Related Experiment Videos
Relationship between prostate specific antigen, prostate volume and age in the benign prostate
G N Collins1, R J Lee, G B McKelvie
1Department of Urology, Royal Infirmary, Stirling.
British Journal of Urology
|April 1, 1993
Summary
Prostate specific antigen (PSA) levels correlate with age and prostate volume in men. Adjusting PSA for these factors may improve prostate cancer diagnosis when used with digital rectal exam and ultrasound.
Area of Science:
- Urology
- Oncology
Background:
- Prostate specific antigen (PSA) is a key biomarker for prostate health.
- Understanding factors influencing PSA levels, such as age and prostate volume, is crucial for accurate interpretation.
- Benign prostatic hyperplasia (BPH) is common in aging men, affecting prostate size and potentially PSA levels.
Purpose of the Study:
- To investigate the independent relationships between prostate specific antigen (PSA) levels, prostate volume, and age in a cohort of men without prostate cancer.
- To determine if age and prostate volume influence PSA levels independently.
- To assess the potential for PSA adjustments based on age and volume for improved diagnostic accuracy.
Main Methods:
- Cross-sectional community survey involving 472 men.
- Data collection included PSA assay, digital rectal examination (DRE), and transrectal ultrasound (TRUS).
- Statistical analysis, including linear regression, was used to examine correlations and independent associations.
Main Results:
- Mean age was 60 years; mean PSA was 2.4 ng/ml, with 85% < 4 ng/ml.
- Modest correlations were observed between PSA, age, and prostate volume.
- Prostate volume increased with age, and PSA showed an independent association with age even after controlling for volume.
Conclusions:
- Both age and prostate volume independently influence prostate specific antigen (PSA) levels.
- The ratio of PSA to prostate volume increases with age.
- Further evaluation is needed to assess the sensitivity and specificity of volume- and age-adjusted PSA in conjunction with DRE and TRUS for prostate cancer diagnosis.